ORGANON & CO

Drinane Juliana Papa’s biggest insider sale at $13.57 highlights Organon’s strategic portfolio rebalancing, not a market warning, and underscores the company’s robust long‑term outlook.

Insider buys hint at hidden value in Sun Pharma’s $12 B acquisition of Organon, promising expanded markets, R&D synergies and upside for investors.

Insider buy signals confidence in Organon ahead of Sun Pharma deal; exec purchase suggests share price may rise as acquisition nears.